These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

562 related articles for article (PubMed ID: 34080180)

  • 1. Magnetic resonance imaging in neuromyelitis optica spectrum disorder.
    Clarke L; Arnett S; Lilley K; Liao J; Bhuta S; Broadley SA
    Clin Exp Immunol; 2021 Dec; 206(3):251-265. PubMed ID: 34080180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early and extensive spinal white matter involvement in neuromyelitis optica.
    Hayashida S; Masaki K; Yonekawa T; Suzuki SO; Hiwatashi A; Matsushita T; Watanabe M; Yamasaki R; Suenaga T; Iwaki T; Murai H; Kira JI
    Brain Pathol; 2017 May; 27(3):249-265. PubMed ID: 27082714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Grey Matter Atrophy and its Relationship with White Matter Lesions in Patients with Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder, and Multiple Sclerosis.
    Cortese R; Battaglini M; Prados F; Gentile G; Luchetti L; Bianchi A; Haider L; Jacob A; Palace J; Messina S; Paul F; Marignier R; Durand-Dubief F; de Medeiros Rimkus C; Apostolos Pereira SL; Sato DK; Filippi M; Rocca MA; Cacciaguerra L; Rovira À; Sastre-Garriga J; Arrambide G; Liu Y; Duan Y; Gasperini C; Tortorella C; Ruggieri S; Amato MP; Ulivelli M; Groppa S; Grothe M; Llufriu S; Sepulveda M; Lukas C; Bellenberg B; Schneider R; Sowa P; Celius EG; Pröbstel AK; Granziera C; Yaldizli Ö; Müller J; Stankoff B; Bodini B; Barkhof F; Ciccarelli O; De Stefano N;
    Ann Neurol; 2024 Aug; 96(2):276-288. PubMed ID: 38780377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD.
    Yan Y; Li Y; Fu Y; Yang L; Su L; Shi K; Li M; Liu Q; Borazanci A; Liu Y; He Y; Bennett JL; Vollmer TL; Shi FD
    Sci China Life Sci; 2016 Dec; 59(12):1270-1281. PubMed ID: 26920678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
    Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
    J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Immunology of Neuromyelitis Optica-Current Knowledge, Clinical Implications, Controversies and Future Perspectives.
    Jasiak-Zatonska M; Kalinowska-Lyszczarz A; Michalak S; Kozubski W
    Int J Mol Sci; 2016 Mar; 17(3):273. PubMed ID: 26950113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brain and spinal cord lesion criteria distinguishes AQP4-positive neuromyelitis optica and MOG-positive disease from multiple sclerosis.
    Bensi C; Marrodan M; González A; Chertcoff A; Osa Sanz E; Chaves H; Schteinschnaider A; Correale J; Farez MF
    Mult Scler Relat Disord; 2018 Oct; 25():246-250. PubMed ID: 30144694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Seronegative Neuromyelitis Optica Spectrum--the challenges on disease definition and pathogenesis.
    Sato DK; Callegaro D; Lana-Peixoto MA; Nakashima I; Fujihara K
    Arq Neuropsiquiatr; 2014 Jun; 72(6):445-50. PubMed ID: 24964112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders.
    Flanagan EP; Weinshenker BG; Krecke KN; Lennon VA; Lucchinetti CF; McKeon A; Wingerchuk DM; Shuster EA; Jiao Y; Horta ES; Pittock SJ
    JAMA Neurol; 2015 Jan; 72(1):81-7. PubMed ID: 25384099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlations among disability, anti-AQP4 antibody status and prognosis in the spinal cord involved patients with NMOSD.
    Hsu JL; Liao MF; Chang KH; Cheng MY; Ro LS
    BMC Neurol; 2021 Apr; 21(1):153. PubMed ID: 33836682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicoradiological comparative study of Aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody associated disease (MOGAD): A prospective observational study and review of literature.
    Nagireddy RBR; Kumar A; Singh VK; Prasad R; Pathak A; Chaurasia RN; Mishra VN; Joshi D
    J Neuroimmunol; 2021 Dec; 361():577742. PubMed ID: 34655992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum.
    Ghosh Md R; Roy D; León-Ruiz M; Das S; Dubey S; Benito-León J
    Qatar Med J; 2022; 2022(3):29. PubMed ID: 35864917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-aquaporin-1 autoantibodies in patients with neuromyelitis optica spectrum disorders.
    Tzartos JS; Stergiou C; Kilidireas K; Zisimopoulou P; Thomaidis T; Tzartos SJ
    PLoS One; 2013; 8(9):e74773. PubMed ID: 24086369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contrasting the brain imaging features of MOG-antibody disease, with AQP4-antibody NMOSD and multiple sclerosis.
    Messina S; Mariano R; Roca-Fernandez A; Cavey A; Jurynczyk M; Leite MI; Calabrese M; Jenkinson M; Palace J
    Mult Scler; 2022 Feb; 28(2):217-227. PubMed ID: 34048323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and MRI measures to identify non-acute MOG-antibody disease in adults.
    Cortese R; Battaglini M; Prados F; Bianchi A; Haider L; Jacob A; Palace J; Messina S; Paul F; Wuerfel J; Marignier R; Durand-Dubief F; de Medeiros Rimkus C; Callegaro D; Sato DK; Filippi M; Rocca MA; Cacciaguerra L; Rovira A; Sastre-Garriga J; Arrambide G; Liu Y; Duan Y; Gasperini C; Tortorella C; Ruggieri S; Amato MP; Ulivelli M; Groppa S; Grothe M; Llufriu S; Sepulveda M; Lukas C; Bellenberg B; Schneider R; Sowa P; Celius EG; Proebstel AK; Yaldizli Ö; Müller J; Stankoff B; Bodini B; Carmisciano L; Sormani MP; Barkhof F; De Stefano N; Ciccarelli O;
    Brain; 2023 Jun; 146(6):2489-2501. PubMed ID: 36515653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative brain lesion distribution may distinguish MOG-ab and AQP4-ab neuromyelitis optica spectrum disorders.
    Yang L; Li H; Xia W; Quan C; Zhou L; Geng D; Li Y
    Eur Radiol; 2020 Mar; 30(3):1470-1479. PubMed ID: 31748853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meningitis as a recurrent manifestation of anti-AQP4/anti-MOG negative neuromyelitis optica spectrum disorder: a case report.
    Zhang C; Zhang K; Chen B; Yin J; Dong M; Qin Y; Yang X
    BMC Neurol; 2021 Mar; 21(1):109. PubMed ID: 33750325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Whole spinal transverse myelitis in neuromyelitis optica spectrum disorder.
    Etemadifar M; Mousavi S; Salari M; Hosseinian SA; Mansouri AR
    Mult Scler Relat Disord; 2024 Jul; 87():105666. PubMed ID: 38749352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders.
    Qin C; Chen B; Tao R; Chen M; Ma X; Shang K; Wu LJ; Wang W; Bu BT; Tian DS
    Mult Scler Relat Disord; 2019 Oct; 35():1-4. PubMed ID: 31276911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MRI Features of Aquaporin-4 Antibody-Positive Longitudinally Extensive Transverse Myelitis: Insights into the Diagnosis of Neuromyelitis Optica Spectrum Disorders.
    Chee CG; Park KS; Lee JW; Ahn HW; Lee E; Kang Y; Kang HS
    AJNR Am J Neuroradiol; 2018 Apr; 39(4):782-787. PubMed ID: 29449281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.